SeaStar Medical Announces Publication of Positive Real-World Experience for QUELIMMUNE SCD-PED Therapy in Pediatric Acute Kidney Injury

DENVER, February 9, 2026 – , a commercial-stage medical technology company focused on developing proprietary solutions to reduce the consequences of hyperinflammation, has announced the publication of a peer-reviewed article in the respected scientific journal . The publication details positive real-world clinical experience with the company’s QUELIMMUNE™ SCD-PED therapy in children suffering from acute kidney injury (AKI).

This milestone represents a significant step forward for pediatric critical care, as it provides independent, real-world evidence supporting the safety, feasibility, and potential clinical benefit of QUELIMMUNE SCD-PED therapy outside of controlled clinical trials. The findings reinforce SeaStar Medical’s mission to improve outcomes for critically ill pediatric patients by addressing dysregulated immune responses that drive organ failure.

Understanding the Burden of Pediatric Acute Kidney Injury

Acute kidney injury is a serious and often life-threatening condition characterized by a sudden decline in kidney function. In pediatric patients, AKI frequently occurs in the context of severe infections, sepsis, cardiac surgery, trauma, or multi-organ dysfunction. Children admitted to intensive care units (ICUs) with AKI face significantly higher risks of prolonged hospitalization, long-term kidney damage, and mortality.

Despite advances in supportive care, treatment options for pediatric AKI remain limited. Current approaches largely focus on managing symptoms and complications rather than addressing the underlying inflammatory processes that contribute to kidney damage and systemic organ failure. This unmet medical need has driven ongoing research into therapies that can modulate the immune system and reduce harmful inflammation.

The Role of Hyperinflammation in Critical Illness

Hyperinflammation is a pathological immune response in which the body releases excessive levels of inflammatory mediators, such as cytokines, in response to infection or injury. While inflammation is a natural defense mechanism, an uncontrolled response can lead to widespread tissue damage, organ dysfunction, and death.

In pediatric AKI, hyperinflammation plays a central role in worsening kidney injury and triggering failure in other organs. Neutrophils and activated immune cells can damage the delicate structures of the kidneys, impair blood flow, and amplify systemic inflammation. Therapies capable of selectively modulating this immune response have the potential to transform outcomes for critically ill children.

What Is QUELIMMUNE SCD-PED Therapy?

QUELIMMUNE SCD-PED therapy is an extracorporeal immunomodulatory device designed to selectively target and deactivate hyperactivated neutrophils and monocytes. Unlike traditional dialysis or filtration systems that focus solely on removing waste products or excess fluid, QUELIMMUNE works by addressing the immune dysregulation that drives inflammation and organ injury.

The therapy is delivered through an extracorporeal circuit, similar to other blood-based treatments commonly used in intensive care settings. As blood passes through the device, QUELIMMUNE modulates immune cell activity, aiming to reduce excessive inflammation while preserving the body’s ability to fight infection.

Importantly, the SCD-PED version of QUELIMMUNE has been specifically designed and adapted for use in pediatric patients, taking into account their smaller blood volumes and unique physiological considerations.

Overview of the Published Real-World Experience

The newly published article in Pediatric Nephrology presents real-world clinical experience from pediatric centers that have utilized QUELIMMUNE SCD-PED therapy in critically ill children with AKI. Real-world evidence is particularly valuable because it reflects how a therapy performs in routine clinical practice, rather than under the controlled conditions of a clinical trial.

The publication describes patient characteristics, clinical settings, treatment protocols, and observed outcomes, offering insights into how QUELIMMUNE therapy integrates into standard ICU care. The authors highlight the feasibility of implementing the therapy in complex pediatric cases and discuss observed trends in patient stabilization and recovery.

Key Findings from the Real-World Data

Safety and Tolerability

One of the most important aspects of introducing any new therapy in pediatric care is safety. According to the published experience, QUELIMMUNE SCD-PED therapy was generally well tolerated in critically ill children. Clinicians reported no unexpected device-related adverse events, supporting the therapy’s favorable safety profile.

This finding is particularly significant given the vulnerability of pediatric ICU patients, who often have multiple comorbidities and are receiving several simultaneous interventions.

Feasibility in Intensive Care Settings

The article also emphasizes the practical feasibility of using QUELIMMUNE SCD-PED therapy in real-world pediatric intensive care units. Healthcare teams were able to integrate the device into existing extracorporeal circuits and workflows, minimizing disruption to standard care.

The ability to deploy the therapy efficiently is crucial for critically ill patients, where time, staffing, and resource constraints can limit the adoption of complex treatments.

Signals of Clinical Benefit

While the publication was not designed to definitively prove efficacy, clinicians observed encouraging signals of potential clinical benefit. These included stabilization of hemodynamics, improvements in inflammatory markers, and trends toward recovery of organ function in some patients.

The authors stress that these observations support continued investigation of QUELIMMUNE therapy in larger, controlled studies, while also providing reassurance to clinicians considering its use in appropriate cases.

Expert Perspectives from the Clinical Community

The publication includes insights from pediatric nephrologists and intensivists who have firsthand experience using QUELIMMUNE SCD-PED therapy. These clinicians highlight the urgent need for innovative approaches in pediatric AKI and express cautious optimism about immunomodulatory strategies.

Several experts note that therapies targeting the immune response represent a paradigm shift in the management of critical illness. Rather than reacting to organ failure after it occurs, immunomodulation aims to interrupt the disease process earlier and reduce downstream damage.

Strategic Importance for SeaStar Medical

For SeaStar Medical, the publication represents more than a scientific achievement. It serves as an important validation of the company’s technology and development strategy. Real-world evidence complements clinical trial data and can play a critical role in building confidence among clinicians, hospital administrators, and regulators.

The company has emphasized its commitment to generating robust clinical evidence to support the adoption of QUELIMMUNE therapy across pediatric and adult indications. This publication strengthens SeaStar Medical’s position as an innovator in the field of immunomodulation.

Implications for Pediatric Healthcare Systems

Pediatric AKI places a substantial burden on healthcare systems due to prolonged ICU stays, high resource utilization, and long-term follow-up needs for survivors. Therapies that can reduce the severity or duration of AKI have the potential to improve not only patient outcomes but also healthcare efficiency.

If further studies confirm the benefits suggested by real-world experience, QUELIMMUNE SCD-PED therapy could become an important adjunct to standard care, helping clinicians manage the inflammatory component of critical illness more effectively.

Regulatory and Development Pathway

SeaStar Medical continues to work closely with regulatory authorities to advance the development and availability of QUELIMMUNE therapy. Real-world evidence publications such as this one can support regulatory discussions by demonstrating how the therapy performs in actual clinical use.

The company has indicated that it plans to expand clinical research efforts, including additional observational studies and prospective trials, to further evaluate outcomes and refine patient selection criteria.

Looking Ahead: The Future of Immunomodulation in Pediatrics

The publication in Pediatric Nephrology contributes to a growing body of literature exploring immunomodulatory therapies in pediatric critical care. As understanding of the immune system’s role in organ failure deepens, treatments like QUELIMMUNE may become increasingly central to managing severe illness.

Future research will focus on identifying which patients are most likely to benefit, determining optimal timing and duration of therapy, and integrating immunomodulation into comprehensive care pathways.

Conclusion

The publication of positive real-world experience with QUELIMMUNE SCD-PED therapy marks an important milestone for SeaStar Medical and for the field of pediatric nephrology. By demonstrating safety, feasibility, and encouraging clinical signals in real-world settings, the article provides valuable insights for clinicians and researchers alike.

As pediatric acute kidney injury continues to pose significant challenges, innovative therapies that address the underlying drivers of disease are urgently needed. QUELIMMUNE SCD-PED therapy represents a promising step toward improving outcomes for some of the most vulnerable patients in healthcare.

#SlimScan #GrowthStocks #CANSLIM